Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.

Part of paid clinical trials in Tucson, Arizona.

Sponsor
Francisco A Moreno
Study ID
NCT07347405
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Obsessive-Compulsive Disorder

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Psilocybin 10 mg — DRUG
    Oral administration of whole dried psilocybin mushrooms contained in a chocolate matrix.
  • Psilocybin 20 mg — DRUG
    Oral administration of whole dried psilocybin mushrooms contained in a chocolate matrix.
  • Psilocybin 30 mg — DRUG
    Oral administration of whole dried psilocybin mushrooms contained in a chocolate matrix.

Study Details

The study tries to improve our treatments for people who have obsessive-compulsive disorder (OCD) by testing psilocybin, a mind altering drug that changes activity in brain areas involved in OCD. 30 patients with moderate or more severe OCD who are not taking mind altering medications or street drugs will participate in a 12 week study. Participants will be assigned (by luck of the draw) to take a low, medium, or high dose whole psilocybin mushroom contained in three chocolate pieces, prepared for this study by the Scottsdale Research Institute.

Key Dates

Start date
May 18, 2026
Status verified
May 2026
Primary completion
Jan 31, 2028
Completion
Jan 31, 2029

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Low dose 10 mg
    Whole dried psilocybin mushroom containing 10 mg of psilocybin will be mixed in a chocolate matrix and administered to the patient.
  • Experimental: Middle dose 20 mg
    Whole dried psilocybin mushroom containing 20 mg of psilocybin will be mixed in a chocolate matrix and administered to the patient.
  • Experimental: High dose 30 mg
    Whole dried psilocybin mushroom containing 30 mg of psilocybin will be mixed in a chocolate matrix and administered to the patient.

Primary Outcome Measure

Yale Brown Obsessive Compulsive Scale [ Time Frame: Baseline, Weekly for 12 weeks (Treatment phase), and Monthly for 12 month (Follow up phase). ]

Central Contacts

  • The clinical and translational research center
    (520) 626-8000
    [email protected]
  • Study Coordinator
    (520) 626-4804

Locations (1)

FacilityCityStateZIPSite coordinators
The Clinical and Translational Sciences Research CenterTucsonArizona85724
Study Coordinator
[email protected]
520-626-4804

Find similar trials in Tucson, AZ

By research site
The Clinical and Translational Sciences Research Center· Tucson, AZ

Related Studies